A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types

Bzhalava, Davit; Guan, Peng; Franceschi, Silvia; Dillner, Joakim; Clifford, Gary M.

doi:10.1016/j.virol.2013.07.015

Cited by 260 publications

(235 citation statements)

References 48 publications

Supporting

Mentioning

201

Contrasting

Unclassified

Order By: Relevance

“…26,27 Findings that most metachronous CIN1 and CIN3 lesions are caused by different HPV genotypes 28 are also in line with our conclusions. Several studies have investigated the clinical relevance of testing for HPV in cervical screening programs, in Europe [29][30][31][32][33][34] and North America.…”

Section: Discussionsupporting

confidence: 90%

Long‐term HPV type‐specific risks of high‐grade cervical intraepithelial lesions: A 14‐year follow‐up of a randomized primary HPV screening trial

Smelov

Elfström

Johansson

et al. 2014

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Quantitative knowledge of the long-term human papillomavirus (HPV) type-specific risks for high-grade cervical intraepithelial neoplasias Grades 2 and 3 (CIN2 and CIN3) is useful for estimating the effect of elimination of specific HPV types and clinical benefits of screening for specific HPV types. We estimated HPV type-specific risks for CIN2 and CIN3 using a randomized primary HPV screening trial followed up for 14.6 years using comprehensive, nationwide registers. Poisson regression estimated cumulative incidences, population attributable proportions (PAR) and incidence rate ratios (IRRs) of high-grade lesions by baseline HPV type, with censoring at date of first CIN2/3 or last registered cytology. Multivariate analysis adjusted for coinfections. IRRs were highest during the first screening round, but continued to be high throughout follow-up (IRRs for CIN3 associated with high-risk (HR) HPV positivity were 226.9, 49.3, 17.7 and 10.3 during the first, second and third screening round and for >9 years of follow-up, respectively). Increased long-term risks were found particularly for HPV Types 16, 18 and 31 and for CIN31 risks. HPV16/18/31/33 had 14-year cumulative incidences for CIN31 above 28%, HPV35/45/52/58 had 14 year risks between 14% and 18% and HPV39/51/56/59/66/68 had risks <10%. HPV16 contributed to the greatest proportion of CIN21 (first round PAR 36%), followed by Types 31, 52, 45 and 58 (7-11%). HPV16/18/31/33/45/52/58 together contributed 73.9% of CIN21 lesions and all HR types contributed 86.9%. In summary, we found substantial differences in risks for CIN2 and CIN3 between different oncogenic HPV types. These differences may be relevant for both clinical management and design of preventive strategies.While cervical cancer is the third most common female cancer worldwide, with an estimated 530,000 new cases diagnosed in 2008, 1 organized cytological screening programs in Europe have reduced the number of annual cervical malignancy cases on the continent from 68,000 diagnosed in 1995 2 to 55,000 in 2008.1 However, cytology has limited sensitivity in detecting the high-grade cervical intraepithelial neoplasias (CIN) Grade 2 (CIN2) and 3 (CIN3) that are the precursor lesions of cervical cancer.3,4 Infection with oncogenic ["highrisk" (HR)] types of human papillomavirus (HPV) is a necessary risk factor in cervical carcinogenesis. 5Several randomized controlled trials (RCTs) have reported that screening with HPV DNA testing has higher sensitivity for detection of high-grade CIN. 4,[6][7][8][9] The estimated CIN21 sensitivity is more than 90% for HPV testing, compared to an average of 55% for cytology.4,6-9 Accordingly, HPV testing affords better protection against invasive cervical cancer. 10The Swedescreen primary HPV screening RCT was started in Sweden in 1997 and explored the effect of a single life-time HPV test as an add-on to an organized population-based cervical screening program. Previous results have shown that the addition of an HPV test resulted in an increased detection of CIN21 in the f...

show abstract

Section: Discussionsupporting

confidence: 90%

Long‐term HPV type‐specific risks of high‐grade cervical intraepithelial lesions: A 14‐year follow‐up of a randomized primary HPV screening trial

Smelov

Elfström

Johansson

et al. 2014

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Human papillomavirus (HPV) has been described as an etiologic factor of several diseases, such as cervical and other anogenital cancers, and a subset of HPV-positive head and neck cancers [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Celecoxib promotes degranulation of CD8+ T cells in HPV-induced lesions of K14-HPV16 transgenic mice

et al. 2016

View full text Add to dashboard Cite

Aims: Human papillomavirus (HPV) is a known biologic carcinogen which is commonly transmitted through sexual intercourse. CD8 + T cells are known effectors against tumour cells and an important prognostic marker in HPV-induced cancers. COX-2 inhibitors enhance CD8 + T cell activity against some cancers. In this work, we sought to study the presence and activation of CD8 + T lymphocytes in lesions from K14-HPV16 transgenic mice and the immunomodulatory effect of celecoxib (CXB) over these cells.Main methods: Skin samples of CXB-treated and untreated HPV16 -/-and HPV16 +/-mice were enzymatically digested and analysed by flow cytometry to assess CD8 + and CD8 + CD107a + T cell infiltrates. Matched skin samples were classified histologically.Key findings: HPV16 +/-mice presented higher CD8 + T cell infiltration than HPV16 -/-animals (P 0.001). Older HPV16 +/-animals showed epidermal dysplasia and increased percentages of CD8 + CD107a + T cells compared with younger animals with hyperplasia (P 0.001), validating this model for testing the effects of celecoxib on CD8 + T cells. CXB-treated HPV16 +/-mice showed higher percentages of CD8 + CD107a + T cells compared with untreated HPV16 +/-animals (P 0.01), but no differences were observed concerning the progression of epidermal lesions.Significance: These findings indicate that celecoxib enhances the degranulation of CD8 + T cells on HPV16-induced lesions, suggesting the potential clinical use of COX-2 inhibitors. Additionally, this study demonstrates the usefulness of the K14-HPV16 mouse model for testing therapeutic immunomodulatory approaches.

show abstract

“…Among HPV genotypes, HPV16 and 18 were considered to have the most potent carcinogenic potential (Dahlström et al, 2010;de Sanjose et al, 2010;Rijkaart et al, 2012;Bzhalava et al, 2013;Tjalma et al, 2013;Wheeler et al, 2014), being associated with about 70% of cervical cancers worldwide (de Sanjose et al, 2010;Li et al, 2011). The powerful carcinogenicity of HPV16/18 made them the most meaningful genotyping targets in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of human papillomavirus 16/18 genotyping in low-grade cervical lesions preceded by mildly abnormal cytology

Cheng

et al. 2017

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Histological low-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia grade 1 (LSIL/CIN1) preceded by normal or mildly abnormal cytology is recommended for conservative follow-up, with no separated management. In this study, we assessed the triage value of human papillomavirus (HPV) 16/18 genotyping in 273 patients with LSIL/CIN1. HPV16/18 genotyping was performed at baseline and follow-up was at 6-monthly intervals for up to 2 years. At each follow-up, women positive for cytology or high-risk HPV (hrHPV) were referred for colposcopy. Enrollment cytology, HPV16/18 genotyping, and questionnaire-obtained factors were linked to the 2-year cumulative progression rate. Univariate and multivariate analyses were performed taking into account time-to-event with Cox proportional hazard regression. The results showed that 190 cases (69.6%) regressed, 37 (13.6%) persisted, and 46 (16.8%) progressed. HPV16/18 positivity (hazard ratio (HR), 2.708; 95% confidence interval (CI), 1.432-5.121; P=0.002) is significantly associated with higher 2-year cumulative progression rate. Sub-analysis by enrollment cytology and age restricted the positive association among patients preceded by mildly abnormal cytology and aged 30 years or older. Immediate treatment is a rational recommendation for the high-risk subgroup, when good compliance is not assured.

show abstract

A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types

Cited by 260 publications

References 48 publications

Long‐term HPV type‐specific risks of high‐grade cervical intraepithelial lesions: A 14‐year follow‐up of a randomized primary HPV screening trial

Long‐term HPV type‐specific risks of high‐grade cervical intraepithelial lesions: A 14‐year follow‐up of a randomized primary HPV screening trial

Celecoxib promotes degranulation of CD8+ T cells in HPV-induced lesions of K14-HPV16 transgenic mice

Prognostic value of human papillomavirus 16/18 genotyping in low-grade cervical lesions preceded by mildly abnormal cytology

Contact Info

Product

Resources

About